$22.00
0.04[0.18%]
At close: May 23
$22.00
0[0.00%]
PreMarket: 6:37AM EDT
Organon Stock (NYSE:OGN), Analyst Ratings, Price Targets, Predictions
Organon & Co has a consensus price target of $27, established from looking at the 29 latest analyst ratings. The last 3 analyst ratings were released from Goldman Sachs, Goldman Sachs, and Piper Sandler on May 6, 2024, May 3, 2024, and April 29, 2024. With an average price target of $21.33 between Goldman Sachs, Goldman Sachs, and Piper Sandler, there's an implied -3.03% downside for Organon & Co from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Piper Sandler
Morgan Stanley
Barclays
Raymond James
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Organon
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/06/2024 | Buy Now | -9.09% | Goldman Sachs | Chris Shibutani | $18 → $20 | Maintains | Neutral | Get Alert |
| 05/03/2024 | Buy Now | -9.09% | Goldman Sachs | Chris Shibutani | $18 → $20 | Maintains | Neutral | Get Alert |
| 04/29/2024 | Buy Now | 9.09% | Piper Sandler | David Amsellem | $22 → $24 | Maintains | Overweight | Get Alert |
| 02/20/2024 | Buy Now | -18.18% | Goldman Sachs | Chris Shibutani | $16 → $18 | Maintains | Neutral | Get Alert |
| 11/22/2023 | Buy Now | — | Piper Sandler | David Amsellem | $32 → $22 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | -27.27% | Goldman Sachs | Chris Shibutani | $33 → $16 | Downgrade | Buy → Neutral | Get Alert |
| 10/25/2023 | Buy Now | 45.45% | Piper Sandler | David Amsellem | $33 → $32 | Maintains | Overweight | Get Alert |
| 10/11/2023 | Buy Now | — | Morgan Stanley | Terence Flynn | $27 → $22 | Maintains | Equal-Weight | Get Alert |
| 09/21/2023 | Buy Now | 27.27% | Barclays | Balaji Prasad | → $28 | Initiates | → Overweight | Get Alert |
| 08/09/2023 | Buy Now | 22.73% | Morgan Stanley | Terence Flynn | $25 → $27 | Maintains | Equal-Weight | Get Alert |
| 05/08/2023 | Buy Now | 13.64% | Morgan Stanley | Terence Flynn | $26 → $25 | Maintains | Equal-Weight | Get Alert |
| 03/16/2023 | Buy Now | 50% | Raymond James | Elliot Wilbur | → $33 | Initiates | → Outperform | Get Alert |
| 11/04/2022 | Buy Now | 9.09% | Morgan Stanley | Terence Flynn | $27 → $24 | Maintains | Equal-Weight | Get Alert |
| 10/14/2022 | Buy Now | 13.64% | B of A Securities | Jason Gerberry | $37 → $25 | Downgrade | Neutral → Underperform | Get Alert |
| 10/12/2022 | Buy Now | 22.73% | Morgan Stanley | Terence Flynn | $35 → $27 | Maintains | Equal-Weight | Get Alert |
| 09/06/2022 | Buy Now | 54.55% | Piper Sandler | David Amsellem | $37 → $34 | Upgrade | Neutral → Overweight | Get Alert |
| 08/05/2022 | Buy Now | 68.18% | B of A Securities | Jason Gerberry | $40 → $37 | Downgrade | Buy → Neutral | Get Alert |
| 07/08/2022 | Buy Now | 54.55% | Morgan Stanley | Terence Flynn | $35 → $34 | Maintains | Equal-Weight | Get Alert |
| 04/27/2022 | Buy Now | 81.82% | Goldman Sachs | Chris Shibutani | → $40 | Initiates | → Buy | Get Alert |
| 04/06/2022 | Buy Now | 59.09% | Morgan Stanley | Terence Flynn | $37 → $35 | Maintains | Equal-Weight | Get Alert |
| 02/22/2022 | Buy Now | 68.18% | Morgan Stanley | David Risinger | $35 → $37 | Maintains | Equal-Weight | Get Alert |
| 10/07/2021 | Buy Now | 59.09% | Piper Sandler | David Amsellem | — | Initiates | → Neutral | Get Alert |
| 09/01/2021 | Buy Now | 95.45% | B of A Securities | Jason Gerberry | — | Initiates | → Buy | Get Alert |
| 08/16/2021 | Buy Now | 59.09% | Morgan Stanley | Matthew Harrison | — | Maintains | Equal-Weight | Get Alert |
| 07/23/2021 | Buy Now | 59.09% | Citigroup | Navann Ty | — | Initiates | → Buy | Get Alert |
| 07/22/2021 | Buy Now | 59.09% | Citigroup | Navann Ty | — | Initiates | → Buy | Get Alert |
| 06/15/2021 | Buy Now | 72.73% | JP Morgan | Chris Schott | — | Initiates | → Neutral | Get Alert |
| 06/11/2021 | Buy Now | 50% | Morgan Stanley | David Risinger | — | Initiates | → Equal-Weight | Get Alert |
| 06/10/2021 | Buy Now | — | Evercore ISI Group | Umer Raffat | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Organon (OGN)?
The latest price target for Organon (NYSE: OGN) was reported by Goldman Sachs on May 6, 2024. The analyst firm set a price target for $20.00 expecting OGN to fall to within 12 months (a possible -9.09% downside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Organon (OGN)?
The latest analyst rating for Organon (NYSE: OGN) was provided by Goldman Sachs, and Organon maintained their neutral rating.
When was the last upgrade for Organon (OGN)?
The last upgrade for Organon & Co happened on September 6, 2022 when Piper Sandler raised their price target to $34. Piper Sandler previously had a neutral for Organon & Co.
When was the last downgrade for Organon (OGN)?
The last downgrade for Organon & Co happened on November 3, 2023 when Goldman Sachs changed their price target from $33 to $16 for Organon & Co.
When is the next analyst rating going to be posted or updated for Organon (OGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Organon, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Organon was filed on May 6, 2024 so you should expect the next rating to be made available sometime around May 6, 2025.
Is the Analyst Rating Organon (OGN) correct?
While ratings are subjective and will change, the latest Organon (OGN) rating was a maintained with a price target of $18.00 to $20.00. The current price Organon (OGN) is trading at is $22.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.